How long does it take to develop resistance to dasatinib?

Dasatinib (Dasatinib) is an inhibitor of multiple tyrosine kinases, including the BCR-ABL kinase associated with chronic myelogenous leukemia and certain other cancers. Dasatinib is indicated for the treatment of adult patients with chronic, accelerated, or myeloid or lymphoblastic-stage chronic myelogenous leukemia (CML) who are resistant or intolerant to previous treatments such as imatinib. It is also indicated for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) that is resistant or intolerant to previous treatments. Taking multiple other drugs together may alter the effectiveness of dasatinib. Myelosuppression is common in patients taking dasatinib.

Drug resistance refers to the weakening or failure of the inhibitory effect of the drug on cancer cells after long-term use of the drug. Some patients may have specific gene mutations in leukemia cells, and these mutations may cause the anti-cancer effect of dasatinib to be reduced. This genetic mutation is called clonal evolution and often occurs during long-term treatment. During long-term treatment, leukemia cells may develop some new genetic mutations that make them no longer sensitive to dasatinib, resulting in reduced therapeutic efficacy. Some patients may have leukemia cells that are resistant to dasatinib due to prior treatment with other anticancer drugs.

In order to reduce the risk of drug resistance, patients strictly follow the doctor's medication instructions and dosage requirements; blood tests and monitoring are performed regularly to evaluate the efficacy of the drug and possible drug resistance. If any adverse reactions or decreased efficacy occur, communicate with your doctor promptly. During drug treatment, maintain good living habits, including a healthy diet, moderate exercise, and adequate rest.